Welcome to Ligand Pharmaceuticals

Ligand is a high-growth company with economic rights to some of the world's most important medicines.

Portfolio
Technologies
Licensing Opportunities

Investor Relations

View Investor Relations

Latest News

Ligand to Report First Quarter 2018 Results on May 8th

Read More

Ligand Enters into Agreement with venBio to Make Worldwide OmniAb® Platform License Accessible to Portfolio Companies

Read More

Ligand Licenses Glucagon Receptor Antagonist Program to Roivant Sciences

Read More

Recent Events

Upcoming Events

Stock Snapshot

LGND
NASDAQ
Volume
Market Cap
Day Range
52-Week Range